Role of Additional Dexamethasone for the Management of Persistent or Recurrent Neovascular Age-related Macular Degeneration under Ranibizumab Treatment.

@article{RezarDreindl2017RoleOA,
  title={Role of Additional Dexamethasone for the Management of Persistent or Recurrent Neovascular Age-related Macular Degeneration under Ranibizumab Treatment.},
  author={Sandra Rezar-Dreindl and Katharina M Eibenberger and Wolf Buehl and Michael Georgopoulos and Guenther Weigert and Christoph Krall and Roman Dunavoelgyi and Ursula M Schmidt-Erfurth and Stefan Sacu},
  journal={Retina},
  year={2017},
  volume={37 5},
  pages={962-970}
}
PURPOSE To assess the efficacy of a combination therapy of intravitreal ranibizumab together with a dexamethasone implant in comparison with ranibizumab monotherapy in neovascular age-related macular degeneration. METHODS Forty eyes of recurrent or persistent neovascular age-related macular degeneration were included in this prospective study. Patients were randomly assigned to two groups. Based on a pro re nata treatment regimen, the first group received intravitreal ranibizumab monotherapy… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS